Compare NATL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | IBRX |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | NATL | IBRX |
|---|---|---|
| Price | $38.74 | $2.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $42.75 | $9.71 |
| AVG Volume (30 Days) | 421.2K | ★ 14.9M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,322,000,000.00 | $82,555,000.00 |
| Revenue This Year | $2.83 | $667.18 |
| Revenue Next Year | $3.96 | $93.03 |
| P/E Ratio | $22.18 | ★ N/A |
| Revenue Growth | 0.63 | ★ 1025.95 |
| 52 Week Low | $22.30 | $1.83 |
| 52 Week High | $42.23 | $4.27 |
| Indicator | NATL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 47.41 |
| Support Level | $38.20 | $2.07 |
| Resistance Level | $39.49 | $2.29 |
| Average True Range (ATR) | 0.82 | 0.13 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 77.15 | 28.00 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.